Sialic Acid Analysis in Laryngeal Cancer

Sialic Acid Analysis in Laryngeal Cancer

Sialic acid is a biomarker of systemic inflammation and is overexpressed in many cancers. CD BioGlyco has developed Strategies for Sialic Acid Analysis that are used to analyze sialic acid in laryngeal cancer research. Welcome customers from all over the world to cooperate with us!

Laryngeal Cancer

Laryngeal cancer is a common head and neck cancer that seriously threatens human health. In the United States, there are approximately 13,000 new cases of laryngeal cancer and 3,500 laryngeal cancer deaths each year. Smoking and heavy drinking are the most risk factors for laryngeal cancer. In addition, advanced age, human papillomavirus (HPV) infection, a low-vegetable diet, and a high-fat diet are also closely related to the occurrence of laryngeal cancer. The histological type of the vast majority of laryngeal cancers is well-differentiated squamous cell carcinoma (SCC). Early-stage throat cancer is cured with surgery or radiation monotherapy.

Sialylation in Laryngeal Cancer

Glycosylation is the most common protein post-translational modification (PTM). Aberrant glycosylation is closely related to the occurrence, development, and metastasis of many tumors, and this phenomenon is also common in SCC. Glycosylation changes serve as biomarkers and therapeutic targets for SCC. Sialic Acid-Specific Bio-Affinity Strategies and liquid chromatography with tandem mass spectrometry (LC-MS/MS) have been used to characterize glycosylation changes in body fluids, primary tumor tissues, and cancer cell lines of SCC patients. For example, Sialic Acid-Specific Lectin is used to analyze sialic acid in tumor tissue sections. Glycosylation changes mainly include abnormal sialylation and abnormal fucosylation. Sialylation levels on the cell surface are affected by sialidases and sialyltransferases. The study found that sialidase-3 (NEU3) mRNA levels were increased in SCC tissue samples compared to normal tissues. Fucosylation has also been implicated in the progression of SCC. Up-regulation of fucosyltransferases such as fucosyltransferases 3 (FUT3) and FUT6 has been found to enhance the expression of sialyl Lewis X (SLex), thereby promoting tumor cell adhesion and transfer.

Glycosylation changes in SCC.Fig.1 Glycosylation changes in SCC. (Rasheduzzaman, 2020)

Case: Sialic Acid Analysis by LC-MS in Laryngeal Cancer

The researchers determined the free and conjugated forms of sialic acid, N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), and free deaminated sialic acid 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) in human laryngeal cancer by LC-MS/MS glycomic method. This method is based on the shifted m/z of LC-MS/MS in negative electrospray ionization (ESI) mode. In conclusion, LC-MS/MS is a highly specific and sensitive method for the quantification of sialic acids in cancer.

CD BioGlyco has developed Strategies for Sialic Acid Analysis to help researchers better analyze sialic acids in cancers. If you have sialic acid analysis needs in laryngeal cancer research, please feel free to contact us for more information.

References:

  1. Wang, F.; et al. LC-MS/MS glycomic analyses of free and conjugated forms of the sialic acids, Neu5Ac, Neu5Gc and KDN in human throat cancers. Glycobiology. 2015, 25(12): 1362-1374.
  2. Rasheduzzaman, M.; et al. Protein glycosylation in head and neck cancers: From diagnosis to treatment. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020, 1874(2): 188422.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.